Peripheral and cardiac effects of a new phosphodiesterase inhibitor in comparison with enoximone.
The effect of the new phosphodiesterse inhibitor R80122 (E)-N-cyclohexyl-N-methyl-2-[[[phenyl(1,2,3,5-tetrahydro-2-oxoimidazo [2,1-b]-quinazolin-7-yl)methylene] amino]oxy]acetamide, (CAS 133718-29-3) on haemodynamic parameters and myocardial oxygen consumption were intraindividually compared with those of enoximone, a clinically established phosphodiesterase inhibitor. In 12 anaesthetised sheep the drugs were given in randomized order as i. v. infusions for 6 min at each setting (10, 20 and 30 micrograms.kg-1.min-1 (R80122) and 32, 64 and 96 micrograms.kg-1.min-1 (enoximone)). R 80122 as well as enoximone caused a significant increase in cardiac inotropism with a simultaneous increase of myocardial oxygen consumption. The peripheral resistance was significantly decreased by both drugs. The haemodynamic effects elicited by the application of equieffective doses of R80122 and enoximone did not show any differences.